APR-246
A19-11184
Phase 1 small_molecule completed
Quick answer
APR-246 for Myeloid Malignancy is a Phase 1 program (small_molecule) at Aprea Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aprea Therapeutics
- Indication
- Myeloid Malignancy
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed